European Academy of Management

Apogee Highlights Corporate Progress and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Monday, November 13, 2023

SAN FRANCISCO and WALTHAM, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other inflammatory and immunology (I&I) indications, today provided business updates and reported third quarter 2023 financial results.

Key Points: 
  • “I am proud of our team’s execution during the third quarter and 2023 overall.
  • Research & Development (R&D) Expenses: R&D expenses for the third quarter of 2023 were $17.1 million, compared to $9.9 million for the third quarter of 2022.
  • General and Administrative (G&A) Expenses: G&A expenses for the third quarter of 2023 were $7.2 million, compared to $0.6 million for the third quarter of 2022.
  • Net Loss: Net loss for the third quarter of 2023 was $20.8 million, compared to the net loss for the third quarter of 2022 which was $19.7 million.

Pusan National University Researchers Dive Deep Into the Safety of JAK Inhibitors for Atopic Dermatitis

Retrieved on: 
Friday, December 15, 2023

In this context, Janus kinase (or JAK) inhibitors are small molecules that have emerged as a promising treatment option for managing AD.

Key Points: 
  • In this context, Janus kinase (or JAK) inhibitors are small molecules that have emerged as a promising treatment option for managing AD.
  • However, the FDA has also issued a boxed warning for JAK inhibitors to include the risk of major adverse events.
  • Since then, many meta-analyses focusing on the safety of JAK inhibitors have been published, but these analyses are fraught with several limitations.
  • Title of original paper: The safety of systemic Janus kinase inhibitors in atopic dermatitis:

Third Harmonic Bio Announces Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 9, 2023

SAN FRANCISCO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced financial results for the third quarter ended September 30, 2023.

Key Points: 
  • On October 31, 2023, Third Harmonic Bio announced the transition of Adrian S. Ray, Ph.D., from Chief Scientific Officer to Scientific Advisor effective November 1, 2023.
  • Additionally, the company announced that Robert Ho, Chief Financial Officer, is departing the organization on November 10, 2023.
  • R&D expenses for the nine months ended September 30, 2023 increased to $18.0 million, from $15.1 million for the same period in 2022.
  • G&A expenses for the nine months ended September 30, 2023 increased to $15.5 million, from $9.0 million for the same period in 2022.

Celldex Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 2, 2023

HAMPTON, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Key Points: 
  • - Phase 2 CSU enrollment complete; topline data by YE 2023 -
    HAMPTON, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.
  • Barzolvolimab is a humanized monoclonal antibody developed by Celldex that binds the KIT receptor with high specificity and potently inhibits its activity.
  • In July 2023, Celldex announced that enrollment to the CSU study (n=208) had been completed and that topline data is anticipated by the end of 2023.
  • Cash Position: Cash, cash equivalents and marketable securities as of September 30, 2023 were $235.3 million compared to $252.7 million as of June 30, 2023.

Nektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV Congress

Retrieved on: 
Friday, October 13, 2023

SAN FRANCISCO, Oct. 13, 2023  /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced new data for rezpegaldesleukin (REZPEG), a first-in-class selective regulatory T-cell (Treg) therapy, in patients with atopic dermatitis (AD) at the 2023 European Academy of Dermatology and Venereology (EADV) Congress. These data were presented by Dr. Jonathan Silverberg, Professor of Dermatology at The George Washington University School of Medicine and Health Sciences and Director of Clinical Research and Contact Dermatitis in a late-breaking oral presentation.

Key Points: 
  • "Data from this presentation demonstrate consistent benefit with REZPEG across multiple clinician and patient-reported outcomes, which were maintained through 36 weeks after treatment ended," said Dr. Jonathan Silverberg.
  • "The sustained post-treatment benefit observed with REZPEG has the potential to alter the need for frequent maintenance dosing for patients with atopic dermatitis.
  • Based on these data, the company is initiating two Phase 2 studies in atopic dermatitis and in alopecia areata.
  • Highlight of the new patient-reported outcomes for the Phase 1b study in atopic dermatitis presented at EADV 2023 for the first time:

Charles Dhanaraj named Academic Director of the Doctor of Business Administration Program

Retrieved on: 
Tuesday, August 15, 2023

Atlanta, Georgia, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Georgia State University’s J. Mack Robinson College of Business has appointed Charles Dhanaraj as academic director of its Doctor of Business Administration (DBA) program.

Key Points: 
  • Atlanta, Georgia, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Georgia State University’s J. Mack Robinson College of Business has appointed Charles Dhanaraj as academic director of its Doctor of Business Administration (DBA) program.
  • In this role, Dhanaraj’s responsibilities include enhancing Robinson’s global reputation for producing practitioner-researchers working as senior-level decision-makers in business as graduates of the college’s professional doctoral program.
  • Bringing with him decades of experience as an academic leader, Dhanaraj has taught in institutions across the world, spanning countries such as India, Singapore, Canada, Switzerland, and the U.S.
  • He succeeds Regents’ Professor Lars Mathiassen, who was the inaugural academic director of the DBA program.

Annual Congress 2023 of the European Academy of Allergy and Clinical Immunology: Study Shows Air Pollution's Impact on Airways of Early-Career Elite Athletes

Retrieved on: 
Friday, June 16, 2023

HAMBURG, Germany, June 16, 2023 /PRNewswire/ -- A recent study conducted in Belgium has revealed the potential effects of air pollution on the airways of early-career elite athletes.

Key Points: 
  • HAMBURG, Germany, June 16, 2023 /PRNewswire/ -- A recent study conducted in Belgium has revealed the potential effects of air pollution on the airways of early-career elite athletes.
  • The abstract was presented on 11th June at the Annual Congress in Hamburg organized by the European Academy of Allergy & Clinical Immunology (EAACI).
  • The research focused on early-career elite athletes aged 12 to 18 years and aimed to investigate the exposure and impact of air pollutants on their airways.
  • Janne Goossens, the PhD researcher of KU Leuven, commented, "Our study highlights the potential impact of air pollution on the airways of early-career elite athletes.

Complete College America Strengthens Its Board of Directors with Three New Members

Retrieved on: 
Thursday, January 19, 2023

“Our nation’s colleges and universities are making significant progress toward improving on-time completion rates, but gaps remain that disproportionately affect part-time students and students of color,” said Yolanda Watson Spiva, president of Complete College America.

Key Points: 
  • “Our nation’s colleges and universities are making significant progress toward improving on-time completion rates, but gaps remain that disproportionately affect part-time students and students of color,” said Yolanda Watson Spiva, president of Complete College America.
  • In that role he provides executive leadership and strategic guidance to support SNHU’s equity and social mobility goals.
  • He is currently a professor in UTA’s departments of Civil Engineering and Mechanical and Aerospace Engineering, and serves as a Complete College America Fellow.
  • The other CCA board members are:
    Robin Martin, Ph.D., former deputy director of strategy, planning and management for the Postsecondary Success team at the Bill & Melinda Gates Foundation

Can-Fite Reports Third Quarter 2022 Financial Results & Provides Clinical Update

Retrieved on: 
Friday, November 25, 2022

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced financial results for the quarter ended September 30, 2022.

Key Points: 
  • Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced financial results for the quarter ended September 30, 2022.
  • The findings were published in the October 2022 supplement of HEPATOLOGY, a premier peer-reviewed journal in the field of liver disease.
  • The decrease in cash during the nine months ended September 30, 2022 is due to the ongoing operations of the Company.
  • The Company's consolidated financial results for the nine months ended September 30, 2022 are presented in accordance with US GAAP Reporting Standards.

Celldex Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, November 9, 2022

HAMPTON, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.

Key Points: 
  • HAMPTON, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.
  • Barzolvolimab is a humanized monoclonal antibody developed by Celldex that binds the KIT receptor with high specificity and potently inhibits its activity.
  • Cash Position: Cash, cash equivalents and marketable securities as of September 30, 2022 were $323.5 million compared to $356.8 million as of June 30, 2022.
  • Financial Guidance: Celldex believes that the cash, cash equivalents and marketable securities at September 30, 2022 are sufficient to meet estimated working capital requirements and fund planned operations through 2025.